DNA News and Research

RSS

DNA, or deoxyribonucleic acid, is the hereditary material in humans and almost all other organisms. Nearly every cell in a person’s body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA).

NHGRI and NIMH fund $45 million to establish Centers of Excellence in Genomic Science

The National Human Genome Research Institute (NHGRI) and National Institute of Mental Health (NIMH), both part of the National Institutes of Health, today announced grants expected to total approximately $45 million to establish new Centers of Excellence in Genomic Science at the Medical College of Wisconsin and University of North Carolina, Chapel Hill as well as to continue support of existing centers at Johns Hopkins University and the University of Southern California.

29 Sep 2009

U.S. PTO to reexamine the patents in Cellectis-Precision BioSciences litigation

Precision BioSciences, Inc. today announced that the United States Patent and Trademark Office (PTO) has granted Precision’s requests for inter partes reexamination of U.S. Patent Nos. 6,610,545 (the ‘545 patent) and 7,309,605 (the ‘605 patent), which Cellectis SA (Alternext: ALCLS) has asserted against Precision in litigation.

29 Sep 2009

World Federation of Neurology awards UT Southwestern director the first Medal for Scientific Achievement

Dr. Roger Rosenberg, director of the Alzheimer's Disease Center at UT Southwestern Medical Center, has been awarded the first Medal for Scientific Achievement by the World Federation of Neurology.

29 Sep 2009

NIH awards Johns Hopkins Epigenetic Center $16.8M to advance genomics research

Johns Hopkins' Center for the Epigenetics of Common Human Disease has been chosen as one of four recipients of a $45 million National Institutes of Health (NIH) grant for Centers of Excellence to advance genomics research. The Hopkins Center will receive $16.8 million over five years.

29 Sep 2009

UCLA discovery raises hope for curing genetic disorders caused by nonsense mutations

UCLA scientists have identified two chemicals that convince cells to ignore premature signals to stop producing important proteins. Published in the Sept. 28 edition of the Journal of Experimental Medicine, the findings could lead to new medications for genetic diseases, such as cancer and muscular dystrophy, that are sparked by missing proteins.

29 Sep 2009

NHGRI announces grant to establish Wisconsin Center of Excellence in Genomics Science

The National Human Genome Research Institute (NHGRI) of the National Institutes of Health today announced an $8 million, three-year grant to establish a Wisconsin Center of Excellence in Genomics Science.

29 Sep 2009

Correlagen Diagnostics to develop diagnostic tests on the Helicos Genetic Analysis Platform

Helicos BioSciences Corporation (NASDAQ: HLCS) today announced the sale of a system and a scientific collaboration with Correlagen Diagnostics Inc., a leading provider of genetic tests for disease diagnosis.

28 Sep 2009

Correlagen to use Helicos Genetic Analysis System for diagnosing genetic disorders

Correlagen Diagnostics Inc., a leading provider of genetic testing for disease diagnosis, today announced the acquisition of a system from and a scientific collaboration with Helicos BioSciences Corporation.

28 Sep 2009

Austrian Institute of Technology adopts Arrayit's Microarray Platform for detecting dangerous pathogens

Arrayit Corporation, a proprietary life sciences and technology leader, disclosed that its Microarray Platform has been adopted by Austrian Institute of Technology.

28 Sep 2009

New scalable solutions for targeted re-sequencing studies from febit holding and Life Technologies

febit holding GmbH and Life Technologies Corporation today announced that they have entered into a strategic co-marketing agreement to provide a new, scalable solution for researchers conducting targeted re-sequencing studies. In addition, febit will expand its Genomic Services Facility at Heidelberg by adding several Applied Biosystems SOLiD™ high-throughput sequencing systems and real-time PCR systems.

28 Sep 2009

Illumina to defend Genome Analyzer System patent infringement suit

Illumina, Inc. today announced that it has been served with a complaint filed on September 21, 2009 in the U.S. District Court in Wilmington, Delaware naming Illumina as a defendant. The complaint names as plaintiffs Life Technologies Corporation; Applied Biosystems LLC; a Russian research institute; two individuals listed as inventors on the asserted patents; and another individual who appears to have an ownership interest in the patents.

From Illumina, Inc. 28 Sep 2009

Study on how epigenetic changes contribute to congnitive decline

The National Institutes of Health has awarded Rush University Medical Center approximately $5.5 million in grants to study how epigenetic changes - chemical modifications to genes that result from diet, aging, stress, or environmental exposures - define and contribute to memory formation and cognitive decline. Results from the studies could profoundly alter the way the medical community understands, diagnoses, and treats Alzheimer's disease, according to the researchers.

28 Sep 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

UK scientists discover new route by which leukaemia develops

CANCER RESEARCH UK SCIENTISTS have discovered a completely new route by which leukaemia develops, according to research published in Nature.

28 Sep 2009

Presentations on Inovio Biomedical's electroporation-delivered DNA vaccines

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today it will make multiple presentations at the Vaccine 3rd Global Congress being held in Singapore October 4th – 6th.

28 Sep 2009

Combined immunodeficiency results in severe health problems

Researchers at the National Institutes of Health have identified a genetic mutation that accounts for a perplexing condition found in people with an inherited immunodeficiency. The disorder, called combined immunodeficiency, is characterized by a constellation of severe health problems, including persistent bacterial and viral skin infections, severe eczema, acute allergies and asthma, and cancer.

28 Sep 2009

Merck, Qiagen pledge cervical cancer tools at CGI, meeting highlights effects of gender inequality

Drugmaker Merck & Co. announced Wednesday at the Clinton Global Initiative's (CGI) annual meeting in New York that it will "donate more than $500 million of its Gardasil cervical cancer vaccine" with the goal of improving women's health in developing countries, Bloomberg reports.

From QIAGEN Manchester Limited 28 Sep 2009

Misregulation of SPAK protein may contribute to B-cell lymphoma development

A group led by Dr. Michael Teitell at UCLA has demonstrated that misregulation of the protein SPAK may contribute to B-cell lymphoma development. Their report can be found in the October 2009 issue of the American Journal of Pathology.

28 Sep 2009

Phase 2 clinical trial results of IMO-2055 announced

Idera Pharmaceuticals, Inc., today announced the presentation of final data from a clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as monotherapy in patients with Renal Cell Carcinoma (RCC). The data are being presented during the Eighth International Kidney Cancer Symposium being held in Chicago, September 25-26, 2009.

28 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

DNA News and Research

Further Reading

NHGRI and NIMH fund $45 million to establish Centers of Excellence in Genomic Science

U.S. PTO to reexamine the patents in Cellectis-Precision BioSciences litigation

World Federation of Neurology awards UT Southwestern director the first Medal for Scientific Achievement

NIH awards Johns Hopkins Epigenetic Center $16.8M to advance genomics research

UCLA discovery raises hope for curing genetic disorders caused by nonsense mutations

NHGRI announces grant to establish Wisconsin Center of Excellence in Genomics Science

Correlagen Diagnostics to develop diagnostic tests on the Helicos Genetic Analysis Platform

Correlagen to use Helicos Genetic Analysis System for diagnosing genetic disorders

Austrian Institute of Technology adopts Arrayit's Microarray Platform for detecting dangerous pathogens

New scalable solutions for targeted re-sequencing studies from febit holding and Life Technologies

Illumina to defend Genome Analyzer System patent infringement suit

Study on how epigenetic changes contribute to congnitive decline

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

UK scientists discover new route by which leukaemia develops

Presentations on Inovio Biomedical's electroporation-delivered DNA vaccines

Combined immunodeficiency results in severe health problems

Merck, Qiagen pledge cervical cancer tools at CGI, meeting highlights effects of gender inequality

Misregulation of SPAK protein may contribute to B-cell lymphoma development

Phase 2 clinical trial results of IMO-2055 announced

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News